Targets › ITGB3
11 programs from 11 companies in 16 trials: 6 Phase 3, 4 Phase 1, 4 Phase 2, 2 Phase 4; Neurology, Oncology, Cardiovascular; next expected readout Dec 2026.
Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor (VWF). Integrin alpha-IIb/beta-3 (ITGA2B:ITGB3) is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. (UniProt, P05106)
Open in Phaseline: the race on ITGB3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Anzhen Hospital | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 4 | Acute Ischemic Stroke | Dec 2026 |
| Second Affiliated Hospital of Soochow University | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 4 | Mild Stroke | Feb 2027 |
| Beijing Tiantan Hospital | Y-4 tablets Integrin alpha-IIb/beta-3 inhibitor | PDE3A, ITGB3, ITGA2B, IL1R1 | Phase 3 | Ischemic Stroke, Acute; Aneurysmal Subarachnoid Hemorrhage; Acute Ischemic Stroke; Stroke Acute … | Dec 2026 |
| General Hospital of Shenyang Military Region | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Stroke, Ischemic | Sep 2027 |
| Weifang Medical University | Tirofiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Stroke, Acute | Feb 2029 |
| Second Affiliated Hospital of Guangxi Medical University | Tirofiban Hydrochloride Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | Acute Ischemic Stroke | – |
| CeleCor Therapeutics | Zalunfiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | ST-elevation Myocardial Infarction (STEMI) | – |
| Erasmus Medical Center | cRGD-ZW800-1 RGD peptide-based fluorescent tracer targeting αvβ3 integrin | ITGAV, ITGB3 | Phase 2 | Squamous Cell Carcinoma of the Larynx | Mar 2028 |
| The First Affiliated Hospital of Xiamen University | 177Lu-AB-3PRGD2 Integrin αvβ3-targeting radioligand therapy (177Lu-labeled) | ITGAV, ITGB3 | Phase 1 | Refractory Solid Tumor | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | fluorescent cRGDY-PEG-Cy5.5-C dots RGD peptide-functionalized silica nanoparticles with fluorescent Cy5.5 dye for imaging int | ITGAV, ITGB3 | Phase 1 | Head and Neck Melanoma | Apr 2027 |
| Peking Union Medical College Hospital | 68Ga-RGD RGD peptide targeting integrin αvβ3 for PET imaging | ITGAV, ITGB3 | Phase 1 | Keloid | Oct 2027 |
Acute Ischemic Stroke (3) Stroke Acute (2) Refractory Solid Tumor (1) Squamous Cell Carcinoma of the Larynx (1) Head and Neck Melanoma (1) ST-elevation Myocardial Infarction (STEMI) (1) Mild Stroke (1) Keloid (1) Stroke, Ischemic (1) Ischemic Stroke, Acute (1) Aneurysmal Subarachnoid Hemorrhage (1) Healthy Adult Male and Female Volunteers (1)
small molecule (11)
The First Affiliated Hospital of Xiamen University (1) Erasmus Medical Center (1) Memorial Sloan Kettering Cancer Center (1) CeleCor Therapeutics (1) Second Affiliated Hospital of Soochow University (1) Peking Union Medical College Hospital (1) General Hospital of Shenyang Military Region (1) Beijing Tiantan Hospital (1) Second Affiliated Hospital of Guangxi Medical University (1) Beijing Anzhen Hospital (1) Weifang Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.